COG A Randomized Phase III Study of Brentuximab Vedotin (SGN-35; IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents: A Groupwide Phase III Study Pediatric CIRB Active Available to Open